News: Umeå, 25 august, 2021.

Lipums CEO Einar Pontén will present Lipum at LSX Nordic Virtual Congress (https://www.lsxleaders.com/lsx-nordic-congress) 6-17 September. The LSX Nordic Congress is annual investment and partnering conference for the Nordic life science and healthcare industry.  

[image]

For further information, please contact: 

Einar Pontén, CEO
E-post: einar.ponten@lipum.se
Mobil: +46 70 578 34 95
Web: www.lipum.se

 

About Lipum
Lipum AB (publ) is a biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in late preclinical stage supported by solid data for the rare disease juvenile idiopathic arthritis and rheumatoid arthritis. Lipum also explores several other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum's unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission, email: ca@gwkapital.se,phone: +46 8 503 000 50.